

DUR Committee

November 18, 2011 Minutes

Members Present:

Robert Carlson, M.D.
William McCormick, Pharm.D.
John Pappenheim, M.D.
Mary-Beth Gardner, ANP
Chad Hope, Pharm.D. (DHSS)
Julie Pritchard, Pharm.D. (Magellan)
C.J. Kim, RPh (DHSS)
Jeff Demain, M.D.

Members Absent:

Dharna Begich, Pharm.D.

- Meeting started at 1:00pm.
- Review of minutes from previous meeting and introduction of C.J. Kim as new DUR coordinator.

ProDUR

- Review of new drugs/indications/PA's
 - **Egrifta** was discussed and modified for PA, passed unanimously. The Committee discussed wait and see, but decided it was better option to PA.
 - **Chantix** was discussed and committee members encouraged not to PA Chantix. The committee wanted to keep the 'Non-Smoking' movement and not to deter a healthy lifestyle change.
 - **Cialis** new indication for BPH was discussed. Recommend PA for 5mg only, passed unanimously.
- Review of New Prescription Medications presented by Chad Hope, recommendations passed unanimously.
- Committee requested that Alaska Medicaid review Lamictal ODT.

Retrospective DUR

- Discuss review criteria
- **Retrospective DUR** (use of tramadol with SSRI or SNRI, increased risk of serotonin syndrome).
 - The profiles were discussed and evaluated for intervention letters to be sent out to the providers.
- Dr. Pappenheim's requested to add a question to the response portion of the intervention letter for adverse events of the combination. (Julie and C.J. will work on).
- William McCormick suggested topic for next RetroDur, Stimulants and Depressant combination.
- Meeting adjourned 4:00pm.